Chaoyu Wang1, Ling Wu1, Chengtao Sun1, Yizhuo Zhang1. 1. Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer Tianjin 300060, China.
Abstract
OBJECTIVE: Currently, the prognosis of standardized uptake value still has no consensus. We evaluated the role of the maximum standardized uptake value (SUVmax) of the MM lesions and the extramedullary disease (EMD) with the highest metabolic activity on PET/CT in predicting survival of newly diagnosed multiple myeloma (MM) patients. METHODS: A total of 123 previously untreated, newly diagnosed patients were enrolled in this study, who were diagnosed at the Tianjin Medical University Cancer Institute and Hospital between September 2008 and February 2018. All patients with available PET/CT information at diagnosis were analyzed. RESULTS: We found that no clinical characteristics were significantly different between the pathological fracture groups. However, laboratory findings including elevated creatinine and anemia at diagnosis corresponded to osteolytic lesions at baseline PET/CT (elevated creatinine, P = 0.024; anemia, P = 0.025). Compared to SUVmax < 5.7 group, the proportion of patients with EMD was significantly high in the SUVmax ≥ 5.7 group (P = 0.046). Multivariate analysis using a Cox proportional hazards model showed that age > 65, poor treatment response and EMD positive were independent poor prognostic factors for newly diagnosed MM patients. CONCLUSION: We confirm the prognostic value of EMD, as detected by PET/CT, in newly diagnosed multiple myeloma patients. Therefore, the presence of EMD in newly diagnosed MM tends to be more important than the SUVmax. IJCEP
OBJECTIVE: Currently, the prognosis of standardized uptake value still has no consensus. We evaluated the role of the maximum standardized uptake value (SUVmax) of the MM lesions and the extramedullary disease (EMD) with the highest metabolic activity on PET/CT in predicting survival of newly diagnosed multiple myeloma (MM) patients. METHODS: A total of 123 previously untreated, newly diagnosed patients were enrolled in this study, who were diagnosed at the Tianjin Medical University Cancer Institute and Hospital between September 2008 and February 2018. All patients with available PET/CT information at diagnosis were analyzed. RESULTS: We found that no clinical characteristics were significantly different between the pathological fracture groups. However, laboratory findings including elevated creatinine and anemia at diagnosis corresponded to osteolytic lesions at baseline PET/CT (elevated creatinine, P = 0.024; anemia, P = 0.025). Compared to SUVmax < 5.7 group, the proportion of patients with EMD was significantly high in the SUVmax ≥ 5.7 group (P = 0.046). Multivariate analysis using a Cox proportional hazards model showed that age > 65, poor treatment response and EMD positive were independent poor prognostic factors for newly diagnosed MMpatients. CONCLUSION: We confirm the prognostic value of EMD, as detected by PET/CT, in newly diagnosed multiple myelomapatients. Therefore, the presence of EMD in newly diagnosed MM tends to be more important than the SUVmax. IJCEP
Authors: Silvia Park; Su Jin Lee; Won Jin Chang; Chi Hoon Maeng; Jung Yong Hong; Moon Ki Choi; Young Saing Kim; Chul Won Jung; Jun Ho Jang; Seok Jin Kim; Won Seog Kim; Joon Young Choi; Kihyun Kim Journal: Acta Haematol Date: 2013-11-26 Impact factor: 2.195
Authors: Abdel Kareem Azab; Phong Quang; Feda Azab; Costas Pitsillides; Brian Thompson; Triona Chonghaile; John T Patton; Patricia Maiso; Val Monrose; Antonio Sacco; Hai T Ngo; Ludmila M Flores; Charles P Lin; John L Magnani; Andrew L Kung; Anthony Letai; Ruben Carrasco; Aldo M Roccaro; Irene M Ghobrial Journal: Blood Date: 2011-11-16 Impact factor: 22.113
Authors: Gary J R Cook; Connie Yip; Muhammad Siddique; Vicky Goh; Sugama Chicklore; Arunabha Roy; Paul Marsden; Shahreen Ahmad; David Landau Journal: J Nucl Med Date: 2012-11-30 Impact factor: 10.057
Authors: Philippe Moreau; Michele Cavo; Pieter Sonneveld; Laura Rosinol; Michel Attal; Annalisa Pezzi; Hartmut Goldschmidt; Juan Jose Lahuerta; Gerald Marit; Antonio Palumbo; Bronno van der Holt; Joan Bladé; Maria Teresa Petrucci; Kai Neben; Jesus san Miguel; Francesca Patriarca; Henk Lokhorst; Elena Zamagni; Cyrille Hulin; Norma Gutierrez; Thierry Facon; Denis Caillot; Lotfi Benboubker; Jean-Luc Harousseau; Xavier Leleu; Hervé Avet-Loiseau; Jean-Yves Mary Journal: J Clin Oncol Date: 2014-06-02 Impact factor: 44.544
Authors: Li Deng; Lin Liu; HaoYuan Ding; ShuMao Zhang; Wei Wang; Wei Zhang; Yi Li Journal: Contrast Media Mol Imaging Date: 2022-02-23 Impact factor: 3.161